• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » ElectroCore seeks commercial partners for non-invasive headache tech

ElectroCore seeks commercial partners for non-invasive headache tech

August 18, 2014 By Brad Perriello

ElectroCore seeks commercial partners for non-invasive headache tech

ElectroCore said it tapped investment bank Piper Jaffray to help it court potential partners to commercialize the non-invasive vagus nerve stimulation treatment for headaches it’s developing.

The self-administered nVNS procedure is designed to treat migraine and cluster headaches, according to a press release; U.S. approval is expected in 2015, the company said. ElectroCore said it’s also working on trials for respiratory and gastric motility disorders, depression and anxiety.

Last year, Basking Ridge, N.J.-based ElectroCore inked a $14 million co-development deal with WaveCore for the nVNS technology.

"The interest from pharma, medical devices and even technology companies has grown considerably over the last six months" founder & CEO J.P. Errico said in prepared remarks. "We wanted to explore all the opportunities for our future, from partnership to remaining independent. We therefore had discussions with several banks to help us with this process and chose Piper Jaffray. We are under no pressure to do a deal as we are fully funded until 2016. However, as we move from proving that nVNS is a promising treatment for primary headache, to rolling out a sales organization we wanted to be mindful of all our options."

ElectroCore said it raised some $50 million from backers including Merck‘s (NYSE:MRK) Global Health Innovation Fund, Easton Capital and Core Ventures for the nVNS device, which has CE Mark approval in the European Union for indications including primary headache, bronchoconstriction, epilepsy, gastric motility disorders, depression and anxiety. South Africa, India, New Zealand, Australia, Colombia, Brazil and Malaysia approved the device for cluster headache, migraine and medication overuse headache; Canada approved it for cluster headache, according to the release.

Filed Under: Funding Roundup, Neuromodulation/Neurostimulation, News Well, Wall Street Beat Tagged With: electroCore, Piper Jaffray

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy